COMMUNIQUÉS West-GlobeNewswire

Denali Therapeutics Announces First-In-Human Dosing Of Its RIPK1 Inhibitor Clinical Program And The Appointment Of Peter Klein To Board Of Directors; Reports Fourth Quarter And Full Year 2017 Financial Results And Business Highlights

19/03/2018 - 13:00

SOUTH SAN FRANCISCO, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI ), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases [...]

INSYS Therapeutics Reiterates Commitment to Compliant and Ethical Business Practices and Advancing Innovative Product Pipeline

19/03/2018 - 13:00

PHOENIX, March 19, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY ), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today released [...]

US Food and Drug Administration (FDA) provides communication to Spectral

19/03/2018 - 13:00

TORONTO, March 19, 2018 (GLOBE NEWSWIRE) -- Spectral Medical Inc., (TSX: EDT ), a Phase III company developing the first targeted treatment for patients with septic shock today announced that the FDA has determined that [...]

BeyondSpring Announces Initiation of Phase 3 Clinical Development for Plinabulin for Prevention of Chemotherapy-Induced Neutropenia

19/03/2018 - 13:00

NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI ), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that the [...]

Dova Pharmaceuticals Signs Exclusive Distribution Agreement with Fosun Pharma For Mainland China and Hong Kong

19/03/2018 - 13:00

DURHAM, N.C., March 19, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA ), a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there [...]

Aclaris Therapeutics Announces Positive Update on Phase 2 Results after a 3-month Follow-Up of A-101 45% Topical Solution for Potential Treatment of Common Warts

19/03/2018 - 13:00

Primary, secondary, and exploratory endpoints of Phase 2 trial met during 8-week treatment period After treatment completed, greater improvement vs. placebo observed in 3-month post-treatment follow-up evaluation If [...]

Share buy-back week 11/2018

19/03/2018 - 12:56

Announcement 19 March 2018 Coloplast – transactions in connection with share buy-back programme As mentioned in Announcement No. 3/2018 Coloplast has initiated the first part of the share buy-back programme totalling up [...]

Mustang Bio to Present at CAR-T Congress USA

19/03/2018 - 12:45

NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO ), a Fortress Biotech (NASDAQ: FBIO ) Company focused on the development of novel immunotherapies based on proprietary chimeric [...]

Cidara Therapeutics Reports Positive Topline Results from Phase 2 STRIVE Trial of Lead Antifungal Rezafungin

19/03/2018 - 12:30

Favorable safety, tolerability, and efficacy observed in novel once-weekly echinocandin for difficult-to-treat invasive fungal infections Phase 3 studies for both treatment and prevention on track to start mid-2018 [...]

Stemline Therapeutics to Present at the Oppenheimer 28th Annual Healthcare Conference

19/03/2018 - 12:30

NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML ), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that Ivan Bergstein, M.D., [...]

Ascendis Pharma Announces Two Posters on Rare Disease Pipeline Programs at ENDO 2018

19/03/2018 - 12:01

- Baseline demographics of TransCon Growth Hormone phase 3 heiGHt Trial presented - - Multiple ascending dose cohorts from TransCon PTH phase 1 clinical trial reinforced infusion-like profile over 24 hours - COPENHAGEN [...]

Agios Announces First Patient Dosed with MAT2A Inhibitor AG-270 in Phase 1 Study in Patients with Advanced Solid Tumors or Lymphoma with an MTAP Deletion

19/03/2018 - 12:01

CAMBRIDGE, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO ), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced dosing of the [...]

Pain Therapeutics Announces FDA Advisory Committee Meeting for REMOXY ER®

19/03/2018 - 12:00

AUSTIN, Texas, March 19, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE ), a drug development company, announced today that the U.S. Food and Drug Administration (FDA) will hold an Advisory Committee [...]

Axsome Therapeutics to Present at 17th Annual Needham Healthcare Conference

19/03/2018 - 12:00

NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM ), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders [...]

The AdVance Study: a Landmark Natural History Study of Adenovirus in Allogeneic Hematopoietic Cell Transplant Shows Strong Correlation Between Disease Burden and Mortality Risk

19/03/2018 - 12:00

DURHAM, N.C., March 19, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX ), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced data from AdVance, the first large, [...]

Motif Bio to present at upcoming investor and scientific conferences

19/03/2018 - 08:00

NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM:MTFB) (NASDAQ: MTFB ), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces that the Company will present at [...]

VALNEVA Reports Positive Phase I Interim Results for Its Lyme Vaccine Candidate VLA15

19/03/2018 - 07:01

Valneva Reports Positive Phase I Interim Results for Its Lyme Vaccine Candidate VLA15 Phase I study (VLA15-101) primary endpoint met No safety concerns associated with VLA15 in any treatment group Encouraging [...]

VALNEVA publie des résultats intermédiaires de Phase I positifs pour son candidat vaccin contre la maladie de Lyme VLA15

19/03/2018 - 07:01

Valneva publie des résultats intermédiaires de Phase I positifs pour son candidat vaccin contre la maladie de Lyme VLA15 Critère d'évaluation principal de l'étude de Phase I (VLA15-101) atteint Aucun problème de [...]

MDxHealth (R): SelectMDx Liquid Biopsy Test for Prostate Cancer included in the 2018 European Association Urology Guidelines

19/03/2018 - 07:01

NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION A significant milestone in MDxHealth's strategy to increase adoption of SelectMDx ® HERSTAL, BELGIUM and IRVINE, CA - 07:00 CEST, March 19, 2018 - MDxHealth SA ( [...]